CHANGING THE PARADIGM OF BREAST CANCER TREATMENT: MBQ-167 AS A FIRST-IN-CLASS METASTATIC BREAST CANCER THERAPEUTIC

$4,398,726FY2025Defense Health AgencyDOD

Mbq Pharma Inc

Investigators